250
Views
14
CrossRef citations to date
0
Altmetric
Original

A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care

, M.Sc.(health econ.), , Ph.D. , M.D., , M.D., , M.Sc. & , Drs. , MSc
Pages 100-108 | Published online: 12 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (7)

Zheng-Yi Zhou, Shawn Sun, Pooja Chopra, Yichen Zhong, Todor Totev & James Signorovitch. (2015) Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder. Journal of Medical Economics 18:11, pages 919-929.
Read now
Andrew P. Yu, Jipan Xie, Arielle Bensimon, Kejal Parikh, Eric Q. Wu, Rym Ben-Hamadi, Steven Blum & M. Haim Erder. (2010) Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study. Journal of Medical Economics 13:4, pages 599-609.
Read now
Eric Q. Wu, Rym Ben-Hamadi, Andrew P. Yu, Jackson Tang, M. Haim Erder & Anjana Bose. (2010) Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons. Journal of Medical Economics 13:2, pages 314-323.
Read now
Alan G. Wade, Delphine Saragoussi, Nicolas Despiégel, Clément François, Florent Guelfucci & Mondher Toumi. (2010) Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK. Current Medical Research and Opinion 26:5, pages 1161-1170.
Read now
Feng Xie, Nicolas Despiegel, Natalya Danchenko & Karina Hansen. (2009) Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. International Journal of Psychiatry in Clinical Practice 13:1, pages 59-69.
Read now
Cyril Höschl & Jaromír Švestka. (2008) Escitalopram for the treatment of major depression and anxiety disorders. Expert Review of Neurotherapeutics 8:4, pages 537-552.
Read now
Raymond W Lam & Lieven Annemans. (2007) Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. Expert Review of Pharmacoeconomics & Outcomes Research 7:6, pages 559-576.
Read now

Articles from other publishers (7)

Yong Wang, Yi-hua Shi, Zhen Xu, Huan Fu, Hua Zeng & Guo-qing Zheng. (2019) Efficacy and safety of Chinese herbal medicine for depression: A systematic review and meta-analysis of randomized controlled trials. Journal of Psychiatric Research 117, pages 74-91.
Crossref
Lieven Annemans, Mélanie Brignone, Sylvain Druais, Ann De Pauw, Aline Gauthier & Koen Demyttenaere. (2014) Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium. PharmacoEconomics 32:5, pages 479-493.
Crossref
Mark J.C. Nuijten, Mélanie Brignone, Florence Marteau, Johan A. den Boer & Erik Hoencamp. (2012) Cost-Effectiveness of Escitalopram in Major Depressive Disorder in the Dutch Health Care Setting. Clinical Therapeutics 34:6, pages 1364-1378.
Crossref
Göran Nordström, Natalya Danchenko, Nicolas Despiegel & Florence Marteau. (2012) Cost-Effectiveness Evaluation in Sweden of Escitalopram Compared with Venlafaxine Extended-Release as First-Line Treatment in Major Depressive Disorder. Value in Health 15:2, pages 231-239.
Crossref
Marieke Krol, Jocé Papenburg, Marc Koopmanschap & Werner Brouwer. (2012) Do Productivity Costs Matter?. PharmacoEconomics 29:7, pages 601-619.
Crossref
Karly P. Garnock-Jones & Paul L. McCormack. (2010) Escitalopram. CNS Drugs 24:9, pages 769-796.
Crossref
Brian Leonard & David Taylor. (2010) Review: Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression. Journal of Psychopharmacology 24:8, pages 1143-1152.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.